N-of-1 trials cost effective in Australian setting

March 2008
PharmacoEconomics & Outcomes News;3/8/2008, Issue 548, p7
The article discusses research being done on the effectiveness of N-of-1 trials as option for increasing patients' access to high-cost medications in the Australian setting. It references a study by P. A. Scuffham et al, published in the January-February 2008 issue of "Value in Health." The data were derived form the trials conducted between 2003 and 2005. Medications evaluated were celecoxib versus sustained-release paracetamol for the treatment of osteoarthritis and gabapentin versus placebo for the treatment of chronic neuropathic pain.


Related Articles

  • Use and Misuse of the P-Value. Lesaffre, Emmanuel // Bulletin of the NYU Hospital for Joint Diseases;2008, Vol. 66 Issue 2, p146 

    The p-value is a widely used tool for inference in clinical studies. However, despite the numerous books and papers published on the basics of statistical inference and, thus, on the p-value, there still seems to be a need to highlight what message the p-value exactly contains (and what it does...

  • Rofecoxib, 25 mg/d, was more effective than rofecoxib, 12.5 mg/d, celecoxib, or acetaminophen in osteoarthritis of the knee. Meyerhoff, John // ACP Journal Club;Jul/Aug2002, Vol. 137 Issue 1, p26 

    Provides information on a study that investigated whether rofecoxib, celecoxib and acetaminophen are effective and safe in patients with symptomatic osteoarthritis of the knee. Study design and setting; Main outcome measures; Main results; Conclusion.

  • The therapeutic effect of clinical trials: understanding placebo response rates in clinical trials -- A secondary analysis. Walach, Harald; Sadaghiani, Catarina; Dehm, Cornelia; Bierman, Dick // BMC Medical Research Methodology;2005, Vol. 5, p26 

    Background and purpose: Placebo response rates in clinical trials vary considerably and are observed frequently. For new drugs it can be difficult to prove effectiveness superior to placebo. It is unclear what contributes to improvement in the placebo groups. We wanted to clarify, what elements...

  • Baseline characteristics and patient reported outcome data of patients prescribed etanercept: web-based and telephone evaluation. Wade, Alan G.; Crawford, Gordon M.; Pumford, Neil; Koscielny, Volker; Maycock, Susan; McConnachie, Alex // BMC Medical Research Methodology;2011, Vol. 11 Issue 1, p91 

    Background: The anti-TNF inhibitor, etanercept is administered as a once or twice weekly subcutaneous injection for the treatment of rheumatoid arthritis, psoriasis, ankylosing spondylitis, psoriatic arthritis and juvenile idiopathic arthritis (JIA). Limited data from the patients' perspective...

  • QRXPHARMA BEGINS PHASE III CLINICAL TRIAL FOR PAIN THERAPY.  // Worldwide Biotech;Jan2008, Vol. 20 Issue 1, p1 

    The article reports on the Phase III clinical trial conducted by QRxPharma for its lead product candidate Q8003IR, an immediate release dual-opioid pain therapy. The trial involved a double-blind, placebo-controlled study that aims to compare the efficacy and safety of four different dosage...

  • A New Approach to the Treatment of Uncomplicated Cystitis: Results of a Randomized Placebo-Controlled Clinical Trial. Salvatorelli, Nicola; García-Larrosa, alejandro; allegrini, alessandro; Pavone, Daniele // Urologia Internationalis;Oct2016, Vol. 97 Issue 3, p347 

    Objective: To assess the efficacy and safety of a new medical device (MD; a capsule whose main component is a crosslinked protein) in the prevention of uncomplicated cystitis recurrences. Methods: Adult women with acute cystitis symptoms and a ciprofloxacin-susceptible isolate in urine culture...

  • Toviaz Top-Line Primary Endpoint Results Positive In Overactive Bladder Study Of Nocturnal Urinary Urgency.  // Biomedical Market Newsletter;11/16/2011, Vol. 21, p67 

    The article reports on the results of the Toviaz, fesoterodine fumarate, Study A0221048 by Pfizer Inc. The study aims to determine the effectiveness and safety of a flexible dose regimen for patients with overactive bladder including nocturnal urinary urgency. It also reveals that treatment with...

  • Drug efficacy by direct and adjusted indirect comparison to placebo: An illustration by Mycobacterium avium complex prophylaxis in HIV. Chu, Jennifer; Sloan, Caroline E.; Freedberg, Kenneth A.; Yazdanpanah, Yazdan; Losina, Elena // AIDS Research & Therapy;2011, Vol. 8, p14 

    Background: Our goal was to illustrate a method for making indirect treatment comparisons in the absence of head-to-head trials, by portraying the derivation of published efficacies for prophylaxis regimens of HIV-related opportunistic infections. Results: We identified published results of...

  • Acetaminophen is as good as celecoxib for degenerative joint disease. Yelland, M. J.; Nikles, C. J.; McNairn, N.; del Mar, C. B.; Schluter, P. J.; Brown, R. M. // Journal of Family Practice;Mar2007, Vol. 56 Issue 3, p181 

    The article discusses the study that determines the effectiveness of acetaminophen, as compared to celecoxib, for treating degenerative joint diseases. The patients received sustained-release paracetamol, sustained-release celecoxib or placebo. They are those with a clinical diagnosis of...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics